Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Curr Med Chem. 2022;29(17):2979-2994. doi: 10.2174/0929867328666210915105929.
Colorectal cancer (CRC) comprises a heterogeneous group of gastrointestinal tract tumors. It is a multifactorial disease, and a plethora of distinct factors are involved in its pathogenesis and pathophysiology. The development of CRC is not limited to genetic changes, but epigenetic and environmental factors are also involved. Among the epigenetic factors, histone deacetylases (HDACs), a group of epigenetic enzymes that regulate gene expression, have been reported to be over-expressed in CRC. HDACs and their inhibitors seem to play an important role in the molecular pathophysiology of CRC. The aim of this review was to define the role of HDAC inhibitors as potential anticancer agents against CRC.
结直肠癌（CRC）包括一组异质性的胃肠道肿瘤。它是一种多因素疾病，有许多不同的因素参与其发病机制和病理生理学。CRC 的发展不仅限于遗传变化，还涉及表观遗传和环境因素。在表观遗传因素中，组蛋白去乙酰化酶（HDACs）是一组调节基因表达的表观遗传酶，据报道在 CRC 中过度表达。HDACs 及其抑制剂似乎在 CRC 的分子病理生理学中发挥重要作用。本综述的目的是定义 HDAC 抑制剂作为潜在的抗 CRC 抗癌药物的作用。
